Discussing Cronos’ Spinach brand, Gorenstein attributed its growth to starting with consumer demand rather than building supply first and later searching for brands to sell it. He contrasted that approach with companies launching many similar brands and “me-too products.” He said Cronos has emphasized differentiated products that build brand equity, citing SOURZ edibles and the company’s newer vape initiatives.More recently, he said the supply-demand balance tightened as capacity came offline while European ...

Cronos Group (NasdaqGM:CRON) FY Conference March 23, 2026 02:30 PM ET Company ParticipantsMike Gorenstein - Chairman, President, and CEOConference Call ParticipantsNone - AnalystNoneIn a minute. Yeah, I think the clock is still. There it is. All right. I'm ready if you're ready. All right. Good morning, everybody. This is the consumer track. We're in the blue room, where we're about to hear from Cronos Group Chairman and CEO Mike Gorenstein. Mike, thank you for being here. Cronos is a leading cannabis LP, w ...

Welcome to the home of The Cannabis Report. I cover the cannabis sector and other sectors. I am most interested in technical stock analysis, option strategies, small cap strategies, and emerging markets. Feel free to contact me with any questions about publicly traded stocks in the cannabis industry.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article mysel ...

TORONTO, March 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the 38th Annual ROTH Conference on Monday, March 23, 2026, at 11:30 AM PDT.A live webcast will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations. About Cronos Group Inc.Cronos is an innovative global cann ...

Industry Overview - The global cannabis industry is evolving with ongoing legalization across various regions, and Canadian cannabis producers play a significant role in this expansion [1][2] - Canada was the first major developed country to legalize recreational cannabis, leading to the establishment of early industry leaders with large cultivation facilities and recognizable brands [2] - Post-legalization, the Canadian cannabis market has faced challenges such as oversupply, price compression, and heavy regulations, prompting many companies to restructure operations [2] Market Dynamics - The industry is shifting towards efficiency and profitability, with companies focusing on cost reduction and margin improvement [3] - International medical cannabis markets, particularly in Europe, are becoming increasingly important, with countries like Germany expanding their medical cannabis programs [3] - The United States remains the largest potential cannabis market, and Canadian companies are preparing strategies for potential entry as federal reform discussions continue [4] Company Strategies - Diversification has become a key strategy for cannabis companies, with expansions into beverages, wellness products, and pharmaceutical research to generate additional revenue streams [5] - Canadian cannabis stocks are characterized by high volatility but still present significant upside potential for investors [5] Key Companies to Watch Tilray Brands Inc. - Tilray is one of the largest global cannabis companies, producing medical and recreational products and operating across cannabis, beverages, and wellness markets [6][10] - The company reported quarterly revenue exceeding $217 million in fiscal 2026, showing modest growth and improved operational efficiency [11] - Tilray's international sales, particularly in Europe, are growing, and the company is positioning itself for potential U.S. legalization through acquisitions and brand development [12][10] Canopy Growth Corporation - Canopy Growth is a major player in the cannabis industry, producing a wide range of products and maintaining strong brand recognition [13][14] - The company reported quarterly cannabis revenue of nearly $52 million, reflecting moderate year-over-year growth, while also focusing on restructuring to improve profitability [18] - Canopy has established a structure for potential U.S. market entry and holds interests in several American cannabis operators [16][17] Cronos Group Inc. - Cronos Group focuses on research and product innovation, emphasizing premium cannabis brands and cannabinoid development [20][24] - The company reported quarterly revenue of approximately $44.5 million, driven by higher sales of cannabis flower and international distribution [25] - Cronos benefits from significant financial backing from Altria, allowing for continued investment in research and development [24][26]

Core Insights - Cronos Group Inc. reported fiscal Q4 2025 earnings with quarterly revenue of $44.53 million, representing a 47.1% year-over-year increase and exceeding expectations by $5.78 million [1] - The revenue growth was attributed to strong demand for leading brands, completion of Cronos GrowCo expansion, and increased contributions from international markets [2] - Gross profit for the quarter was $16.2 million, an increase of $5.4 million year-over-year, driven by a higher average selling price due to a favorable sales mix from Israel and other international markets [2] Future Outlook - The company is optimistic about its acquisition of CanAdelaar, which will facilitate its entry into the European market [3] - Cronos Group Inc. is a cannabinoid company that cultivates, produces, and markets cannabis products globally, offering a variety of products under brands such as Spinach, Lord Jones, and PEACE NATURALS [3]

Industry Overview - The cannabis industry is experiencing significant expansion, with increasing collaboration among businesses to create innovative products and a growing global demand for cannabis [1][2] - Despite market challenges, investors are optimistic about the long-term profitability of cannabis stocks, particularly in the US, Canada, Europe, and other global markets [2] Market Outlook - The year 2026 is projected to be a promising time for shareholders in the cannabis sector, with expectations of higher trading levels [3] - The success of pot stocks does not guarantee better trading conditions, indicating that various factors influence the sector's trading performance [3] Company Highlights - **Cronos Group Inc.**: Engages in the cultivation, production, distribution, and marketing of cannabis products internationally [4] - **Aurora Cannabis Inc.**: Reported a 47% year-over-year increase in net revenue for Q4 2025, reaching $44.5 million, and a 25% increase for FY 2025, totaling $146.6 million. The company has an industry-leading balance sheet with $832 million in cash and equivalents [7][9] - **SNDL Inc.**: Focuses on the production, distribution, and sale of cannabis products for the adult-use market in Canada. The company is set to report its Q4 2025 earnings on March 12, 2026 [9][11]

Core Insights - Cronos Group Inc. (NASDAQ:CRON) is recognized as one of the best pot stocks to buy according to hedge funds, with 19 hedge funds holding stakes in the company as of Q3 2025 [4] Group 1: Analyst Ratings and Price Targets - TD Securities initiated coverage of Cronos Group with a Buy rating and a price target of C$4.50, highlighting its portfolio of iconic Canadian cannabis brands and scalable cost structure [2] - Canaccord analyst Kenric Tyghe also initiated coverage with a Buy rating and a price target of C$4.25, emphasizing the importance of the acquisition of CanAdelaar and the expansion of Cronos Growing Company for enhancing vertical integration and international reach [3] Group 2: Company Overview - Founded in 2012 and headquartered in Toronto, Cronos Group Inc. is a cannabinoid company that cultivates, produces, and markets cannabis products globally, offering a range of products including dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under brands like Spinach, Lord Jones, and PEACE NATURALS [4]

Core Insights - Cronos Group reported a record year in 2025, with organic net revenue growth of 25% and significant increases in quarterly and full-year metrics, including net revenue, gross profit, and adjusted EBITDA [4][7] - The company achieved a fourth-quarter net revenue of $44.5 million, representing a 47% year-over-year increase, driven by higher cannabis flower and extract sales in various markets [3][7] - Adjusted gross margin for the full year was 43%, although it dipped to 36% in Q4 due to production quality issues related to expansion [2][7] Financial Performance - Fourth-quarter gross profit was $16.2 million, yielding a 36% margin, which improved by 670 basis points compared to Q4 2024 [2] - Consolidated net revenue for Q4 reached $44.5 million, up 47% year-over-year, attributed to increased sales in Israel, Canada, and other countries [3] - The full-year adjusted gross margin was reported at 43%, with management indicating this as a reasonable expectation for future performance [7] Market Expansion - International revenue saw significant growth, with Israel net revenue increasing by 52% and other international markets rising by 68% year-over-year [5][11] - The company is acquiring CanAdelaar for EUR 57.5 million (approximately $67.5 million) to establish a presence in the Netherlands' legal adult-use cannabis market [14][15] - Cronos emphasized strong consumer demand in Canada and ongoing expansion in Israel as key growth drivers [4] Product Development and Brand Performance - Spinach emerged as a leading brand in Canada, becoming the second overall vape brand and the top brand in vape cartridges [6][8] - SOURZ maintained a strong market position in edibles, achieving nearly 22% market share in Q4 [9][10] - The company launched Spinach PUFFERZ, an all-in-one vape device, with broader distribution expected in early 2026 [9] Balance Sheet and Capital Allocation - Cronos ended the quarter with approximately $832 million in cash and no debt, indicating a strong liquidity position [5][17] - The company has an active share repurchase program and plans to continue this strategy while exploring disciplined M&A opportunities [18][19] - Management indicated a lower annual capital expenditure expectation of under $10 million based on current operational needs [21]

Investment Philosophy - The company emphasizes a classical value-oriented framework for identifying stocks with a sufficient margin of safety, focusing on discrepancies between underlying business value and market price [1] - The investment approach is bottom-up and sector-agnostic, treating stocks as part ownership of a business rather than mere tickers [1] Communication and Engagement - The company encourages open discussion and clarification on stock ideas, inviting queries from interested parties [1]